Balance Sheet Components - Assets and Liabilities Held For Sale (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue of biosimilars portfolio		$ 166.9	$ 336.0
Liabilities held for sale		285.1	285.1	$ 0.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		179.1	179.1
Inventories		168.5	168.5
Prepaid expenses and other current assets		15.4	15.4
Intangible assets, net		59.9	59.9
Goodwill		936.9	936.9
Other assets		105.6	105.6
Accounts payable		112.9	112.9
Accounts payable		$ 172.2	$ 172.2
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Scenario, Forecast | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront payment subject to certain adjustments	$ 2,000.0
Percent ownership after transaction	12.90%
Additional cash payments to be received	$ 335.0
Term of transition services agreement	2 years